Current Perioperative Care in Pancreatoduodenectomy: A Step-by-Step Surgical Roadmap from First Visit to Discharge
- PMID: 37173964
- PMCID: PMC10177600
- DOI: 10.3390/cancers15092499
Current Perioperative Care in Pancreatoduodenectomy: A Step-by-Step Surgical Roadmap from First Visit to Discharge
Abstract
Pancreaticoduodenectomy (PD) is a mainstay in the management of periampullary tumors. Treatment algorithms increasingly employ a multimodal strategy, which includes neoadjuvant and adjuvant therapies. However, the successful treatment of a patient is contingent on the execution of a complex operation, whereby minimizing postoperative complications and optimizing a fast and complete recovery are crucial to the overall success. In this setting, risk reduction and benchmarking the quality of care are essential frameworks through which modern perioperative PD care must be delivered. The postoperative course is primarily influenced by pancreatic fistulas, but other patient- and hospital-associated factors, such as frailty and the ability to rescue from complications, also affect the outcomes. A comprehensive understanding of the factors influencing surgical outcomes allows the clinician to risk stratify the patient, thereby facilitating a frank discussion of the morbidity and mortality of PD. Further, such an understanding allows the clinician to practice based on the most up-to-date evidence. This review intends to provide clinicians with a roadmap to the perioperative PD pathway. We review key considerations in the pre-, intra-, and post-operative periods.
Keywords: enhanced recovery after surgery; frailty; mitigation strategies; pancreatic fistula; pancreatoduodenectomy; preoperative risk.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
References
-
- De Wilde R.F., Besselink M.G.H., van der Tweel I., de Hingh I.H.J.T., van Eijck C.H.J., Dejong C.H.C., Porte R.J., Gouma D.J., Busch O.R.C., Molenaar I.Q., et al. Impact of Nationwide Centralization of Pancreaticoduodenectomy on Hospital Mortality. Br. J. Surg. 2012;99:404–410. doi: 10.1002/bjs.8664. - DOI - PubMed
-
- Bassi C., Marchegiani G., Giuliani T., Di Gioia A., Andrianello S., Zingaretti C.C., Brentegani G., De Pastena M., Fontana M., Pea A., et al. Pancreatoduodenectomy at the Verona Pancreas Institute: The Evolution of Indications, Surgical Techniques, and Outcomes: A Retrospective Analysis of 3000 Consecutive Cases. Ann. Surg. 2022;276:1029–1038. doi: 10.1097/SLA.0000000000004753. - DOI - PubMed
-
- Van Roessel S., van Veldhuisen E., Klompmaker S., Janssen Q.P., Abu Hilal M., Alseidi A., Balduzzi A., Balzano G., Bassi C., Berrevoet F., et al. Evaluation of Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. JAMA Oncol. 2020;6:1733–1740. doi: 10.1001/jamaoncol.2020.3537. - DOI - PMC - PubMed
-
- Winter J.M., Cameron J.L., Campbell K.A., Arnold M.A., Chang D.C., Coleman J., Hodgin M.B., Sauter P.K., Hruban R.H., Riall T.S., et al. 1423 Pancreaticoduodenectomies for Pancreatic Cancer: A Single-Institution Experience. J. Gastrointest. Surg. 2006;10:1199–1211. doi: 10.1016/j.gassur.2006.08.018. discussion 1210–1211. - DOI - PubMed
-
- Oettle H., Neuhaus P., Hochhaus A., Hartmann J.T., Gellert K., Ridwelski K., Niedergethmann M., Zülke C., Fahlke J., Arning M.B., et al. Adjuvant Chemotherapy with Gemcitabine and Long-Term Outcomes among Patients with Resected Pancreatic Cancer: The CONKO-001 Randomized Trial. JAMA. 2013;310:1473–1481. doi: 10.1001/jama.2013.279201. - DOI - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources